Liver cirrhosis and chronic liver diseases impose a substantial and growing health burden globally, with sub-Saharan Africa (SSA) disproportionately affected. Leveraging Global Burden of Disease 2021 data and Bayesian hierarchical models, we quantified mortality and disability trends in SSA from 1990 to 2021 and projected disease burden through 2035, incorporating scenarios for hepatitis B vaccination scale-up. In 2021, liver cirrhosis accounted for an estimated 181,311 deaths in SSA, despite a 29% decline in age-standardized death rates (ASDR) since 1990. Absolute deaths increased by 65%, predominantly driven by hepatitis B (37%), hepatitis C (28%), and alcohol-related cirrhosis (17%). Disability-adjusted life years (DALYs) surged by 76%, from approximately 1.05 million in 1990 to 1.85 million in 2021, highlighting rising absolute disability alongside a 29% reduction in age-standardized DALYs. Mortality and disability burdens were highest in Somalia, Central African Republic, and Guinea-Bissau. Males bore nearly twice the burden of females. While death rates declined across all socio-demographic strata, absolute deaths rose by 55-86%. Projections to 2035 suggest further potential reductions in mortality from hepatitis B (up to 21.5%), hepatitis C (up to 18.7%), and alcohol-related cirrhosis, while the burden of non-alcoholic fatty liver disease is expected to remain stable or increase slightly. Scaling up hepatitis B vaccination could further avert 27% of related deaths by 2035. These findings reveal persistent and widening disparities in cirrhosis burden across SSA, underscoring the urgent need for integrated, context-specific interventions combining viral hepatitis control with metabolic liver disease management to improve equitable liver health outcomes.

The authors have declared no competing interest.

This study did not receive any funding

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Global Burden of Disease (GBD) (https://vizhub.healthdata.org/gbd-results).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data generated or analysed during this study are included in this published article and its Supplementary Material. Further inquiries can be directed to the corresponding author.